Disease · MONDO_0006632
osteoarthritis, hand
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. osteoarthritis, hand. Diseases, record MONDO_0006632. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006632
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- osteoarthritis, hand
- Open Targets ID
- MONDO_0006632
- Other names
- osteoarthritis of the hand
- Highest stage of its drugs
- Phase 3, for 3 of its 12 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| HYDROXYCHLOROQUINE | CHEMBL1535 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHYLPREDNISOLONE ACETATE | CHEMBL1364144 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IGURATIMOD | CHEMBL2107455 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GEVOKIZUMAB | CHEMBL1743026 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OTILIMAB | CHEMBL2109433 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BAZEDOXIFENE | CHEMBL46740 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXTROSE | CHEMBL1222250 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DICLOFENAC SODIUM | CHEMBL1034 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets64
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 1 | Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 3 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 3 | https://conductscience.org/library/genes/56901 | Drugs and targets |
| CSF2 | Granulocyte-macrophage colony-stimulating factor | 1 | Granulocyte-macrophage colony-stimulating factor inhibitor | Phase 2 | https://conductscience.org/library/genes/1437 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Unknown | https://conductscience.org/library/genes/1719 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor modulator | Unknown | https://conductscience.org/library/genes/2099 | Drugs and targets |
| ESR2 | Estrogen receptor | 1 | Estrogen receptor modulator | Unknown | https://conductscience.org/library/genes/2100 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Phase 3 | https://conductscience.org/library/genes/2820 | Drugs and targets |
| IL1B | Interleukin-1 beta | 1 | Interleukin-1 beta negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/3553 | Drugs and targets |
1 to 10 of 64
See all 64 targetsTrials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02683785 | A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis | Phase 2 | 44 | 2018-12-14 | Osteoarthritis | OTILIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02293564 | Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand | Not applicable | 312 | Osteoarthritis | GEVOKIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT07371572 | The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis | Phase 3 | 212 | Hand Osteoarthritis | METHYLPREDNISOLONE ACETATE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01148043 | Pharmacological Treatment In Osteoarthritis | Phase 3 | 200 | Osteoarthritis | HYDROXYCHLOROQUINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05216757 | Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO) | Phase 2/3 | 150 | Hand Osteoarthritis, Inflammatory Arthritis | IGURATIMOD | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06367283 | Metformin Treatment of Patients with Hand Osteoarthritis | Phase 3 | 150 | Hand Osteoarthritis | METFORMIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03693833 | CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis. | Phase 2 | 136 | Psoriatic Arthritis, Hand Osteoarthritis | CANNABIDIOL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03911570 | Crystalline Glucosamine Sulfate Therapy in Hand Osteoarthritis | 108 | Hand Osteoarthritis | GLUCOSAMINE SULFATE | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT04402047 | Electroacupuncture vs Topical Diclofenac Sodium Gel for Patients With Hand Osteoarthritis | Not applicable | 108 | Hand Osteoarthritis | DICLOFENAC SODIUM | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06281184 | A 30-month Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate in Erosive Hand OA. | 108 | Hand Osteoarthritis, Erosive Osteoarthritis | METHOTREXATE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 13
See all 13 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| GSK3196165 180mg vs Placebo: deaths from any cause | 0 of 22 | 0 of 22 | 44 | NCT02683785 | Trial comparisons |
| GSK3196165 180mg vs Placebo: serious adverse events | 2 of 22 | 1 of 22 | 44 | NCT02683785 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006632
GET https://conductscience.org/api/diseases/v1/MONDO_0006632/targets?page=2